Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 3/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056346 | 0.98 | MTNR1A (0.34) | MTNR1AMTNR1BACLYNR1H2ALDH1A1 | |
| SCHEMBL3056676 | 0.92 | MTNR1A (0.34) | MTNR1AMTNR1BACLYNR1H2ALDH1A1 | |
| SCHEMBL3056705 | 0.91 | ACLY (0.35) | MTNR1AMTNR1BACLYNR1H2ALDH1A1 | |
| SCHEMBL3057579 | 0.90 | MTNR1A (0.34) | MTNR1AMTNR1BACLYNR1H2ALDH1A1 | |
| SCHEMBL3055877 | 0.85 | MTNR1A (0.39) | MTNR1AMTNR1BNR1H2 | |
| SCHEMBL3056343 | 0.85 | MTNR1A (0.39) | MTNR1AMTNR1BNR1H2 | |
| SCHEMBL5090561 | 0.81 | MTNR1A (0.35) | MTNR1AMTNR1BACLYNR1H2ALDH1A1 | |
| SCHEMBL3052808 | 0.79 | BRD4 (0.39) | MTNR1AMTNR1BNR1H2ALDH1A1MEN1 | |
| SCHEMBL3056704 | 0.79 | BRD4 (0.38) | MTNR1AMTNR1BNR1H2 | |
| SCHEMBL3056674 | 0.78 | MTNR1A (0.39) | MTNR1AMTNR1BNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492428-B2 | Small-molecule botulinum toxin inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100260778-A1 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2010-10-14 | — | — | US | disclosed |
| WO-2008051197-A2 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260778-A1 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS | BTD, RAC2, BTN3A1 | MTNR1A 992/4885MTNR1B 759/4885ACLY 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.